Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
-
Furthermore a recently published network meta analysis inclu
2024-10-14
Furthermore, a recently published network meta-analysis including 30 trials in patients with hypertension and diabetes demonstrated that ARBs have efficacy similar to that of ACEIs for all-cause and cardiovascular mortality (HR 0.95, 95% CI 0.73 to 1.30 and HR 1.23, 95% CI 0.64 to 2.78, respectively
-
br Materials and Methods br Author
2024-10-14
Materials and Methods Author Contributions Conflicts of Interest Acknowledgments We thank Francine Jodelka for technical assistance and Gopal Thinakaran for the CTM-1 antibody. This work was financially supported by RFUMS internal research funding and NIHS10 OD 010662. Introduction A
-
br Introduction The development and plasticity of synapses i
2024-10-14
Introduction The development and plasticity of synapses involve the timely recruitment of a plethora of proteins on both pre- and postsynaptic sides through ill-defined mechanisms. At excitatory synapses, two of the major proteins that are dynamically recruited postsynaptically are the Ca2+/calmo
-
We have previously reported that
2024-10-12
We have previously reported that interfering with Salmeterol xinafoate assembly dynamics by knocking down cofilin-1 in hMSCs increased polymerized actin that promoted osteoblast cell differentiation through a mechanism of enhancing focal adhesion kinase (FAK), p38 and c-Jun N-terminal kinase (JNK)
-
br AChE variants and their functions The AChE
2024-10-12
AChE variants and their functions The AChE gene generates several splice variants of AChE which are designated as hydrophobic (H), readthrough (R) and tailed (T) forms differing in membrane association and also localisation on a tissue and sub-cellular level. They all undergo significant posttran
-
ACE inhibition is often thought
2024-10-12
ACE inhibition is often thought to play a central role in the mechanisms of blood pressure reduction in vivo, and most ACE inhibitory (ACEi) peptides were characterized based on in vitro ACE inhibition. A relationship between in vitro ACE inhibition and antihypertensive activity, however, is not app
-
The diagnosis of ICP is currently based
2024-10-12
The diagnosis of ICP is currently based on the presence of pruritus, raised fasting serum TBS levels above 10μmol/L, and/or elevated serum transaminases (in the absence of diseases that cause cholestasis or pruritus) as well as spontaneous relief of signs and symptoms within four to six weeks after
-
br Conflict of interest br Introduction Ovarian cancer is th
2024-10-12
Conflict of interest Introduction Ovarian cancer is the most lethal gynecological malignancy, and ranks as the fifth leading cause of cancer death among women. The American Cancer Society estimates that about 22,280 new ovarian cancer cases and 14,240 deaths will occur in the United States in
-
br Materials and methods br Results In order
2024-10-12
Materials and methods Results In order to evaluate changes in the amount of PKC-θ expressed by MEL cells at different stages of the cell cycle, we measured the level of the kinase in cells collected from cultures containing 90% of cells in the interphase or 80% cells synchronized at the metaph
-
The major phase trial NCT enrolled participants with
2024-10-11
The major phase 2 trial (NCT01343966) enrolled 431 participants with mild to moderate AD who received either low-dose SC crenezumab 300 mg or placebo biweekly (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks 38, 40. No significant treatment benef
-
NVP-LCQ195 receptor WKY and SHR strains have
2024-10-11
WKY and SHR strains have important differences mainly in their sympathetic status but also in the activity of the RAS. The development of hypertension in SHR is clearly related to an increase in sympathetic activity [51], [11]. In addition, increased renal sympathetic nerve activity led to an increa
-
The preferential expression of ALOX B in human macrophages m
2024-10-11
The preferential expression of ALOX15B in human macrophages may explain why human genetic studies investigating the association of ALOX15 with cardiovascular disease did not show consistent results. Two rare functional polymorphisms have been characterized in the ALOX15 gene, which leads to increase
-
The results of cell culture models
2024-10-11
The results of cell culture models were further supported by in vivo studies in mice treated with PXR and/or AhR agonists, PCN and β-NF. In these mice, AhR-regulated cyp1a1, and cyp1a2 were suppressed by PXR activation as determined by real time Q-PCR (Fig. 3). The level of PXR mRNA was not changed
-
Renal cell carcinoma RCC accounts for more than
2024-10-11
Renal cell carcinoma (RCC) accounts for more than 12,000 cancer deaths in the United States (Jemal et al., 2003). The current treatment includes surgical resection followed by interleukin-2 or Interferon-α treatment. Some patients experience distant metastatic lesions of RCC. In the last 5 years, re
-
A 967079 mg The altered frequency of CD T cells in LO mice
2024-10-11
The altered frequency of CD4+ T A 967079 mg in 5-LO−/− mice led us to hypothesize that these leukocytes could be exerting a primary control of the inflammatory response. In fact, the lack of 5-LO resulted in the accumulation of CD4+CD25+ cells expressing Treg markers. It is plausible to speculate t
14379 records 22/959 page Previous Next First page 上5页 2122232425 下5页 Last page